Abstracts tagged "large vessel vasculitis"

Abstract Number: 767 • 2019 ACR/ARP Annual Meeting
Outcome Measures in Large-Vessel Vasculitis: Relationships Between Patient, Physician, Imaging, and Laboratory-Based Domains
Casey A. Rimland¹, Kaitlin Quinn ², Joel S. Rosenblum ³, Mollie Schwartz ⁴, K Bates Gribbons ⁵, Elaine Novakovich ⁶, Antoine Sreih ⁷, Peter Merkel ⁷, Mark A. Ahlman ⁸ and Peter C. Grayson ⁹, ¹National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, Chapel Hill, NC, ²Georgetown University Hospital/National Institutes of Health, Washington, DC, ³National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, Bethesda, MD, ⁴University of Maryland, Baltimore, MD, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁶National Institutes of Health, Bethesda, MD, ⁷University of Pennsylvania, Philadelphia, PA, ⁸Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, Bethesda, MD, ⁹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health, Bethesda, MD, Bethesda, MD
Background/Purpose: Large-vessel vasculitis (LVV) is characterized by inflammation of the aorta and its major branches. The most common forms of LVV include giant cell arteritis…
Abstract Number: 798 • 2019 ACR/ARP Annual Meeting
Development of Large Vessel Vasculitis Including Aortitis in a Patient with Deficiency of the IL-1 Receptor Antagonist (DIRA) Points to Converging Roles of IL-1 and TNF in Vascular Pathogenesis Recapitulating Findings from a Murine Model
Gina Montealegre Sanchez¹, Adriana de Jesus ¹, Jenna Wade ², Katherine Townsend ¹, Arianne Soldatos ³, Alessandra Brofferio ⁴, Peter C. Grayson ⁵, Ginger Janow ⁶ and Raphaela Goldbach-Mansky ¹, ¹Translational Autoinflammatory Disease Section/NIAID/NIH, Bethesda, ²Translational Autoinflammatory Diseases Section/NIAID/NIH, Bethesda, ³NIH/NINDS, Bethesda, ⁴NIH/NHLBI, Bethesda, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health, Bethesda, MD, Bethesda, MD, ⁶Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center, NJ
Background/Purpose: Deficiency of interleukin-1-receptor antagonist (DIRA) is a rare autoinflammatory disease caused by autosomal recessive loss of function mutations in IL1RN and characterized by early-onset generalized pustulosis,…
Abstract Number: 1210 • 2019 ACR/ARP Annual Meeting
Utilization of a Multispecialty Team for the Diagnosis of Giant Cell Arteritis Reduces Patient Morbidity
Arash Hassantoufighi ¹, Rachel Lu-Do¹, Mamta Sherchan ¹, Christopher Collins ¹, Joshpaul Dhillon ² and Florina Constantinescu ¹, ¹MedStar Washington Hospital Center, Department of Rheumatology, Washington, DC, ²MedStar Washington Hospital Center, Department of Internal Medicine, Washington, DC
Background/Purpose: Giant Cell Arteritis (GCA) is an autoimmune vasculitis, most common in older adults with a peak incidence in the seventh decade. The diagnosis is…
Abstract Number: 1964 • 2019 ACR/ARP Annual Meeting
A Role for Microbiota in the Pathophysiology of Takayasu Arteritis (TAK) and Giant Cell Arteritis (GCA)
Anne Desbois¹, Dragos Ciocan ², David Saadoun ¹, Gabriel Perlemuter ³ and Patrice Cacoub ⁴, ¹GHPS, Paris, France, ²Hôpital Antoine Beclere, Clamart, France, ³Hôpital Clamart, Paris, France, ⁴AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Paris, France
Background/Purpose: The pathogenesis of Large Vessel Vasculitis (LVV) is not well understood. There is increasing evidence of a close link between intestinal dysbiosis and systemic…
Abstract Number: 819 • 2018 ACR/ARHP Annual Meeting
Use of Takayasu Arteritis Damage Score (TADS) to Measure Damage in Takayasu Arteritis
Sivakumar Mambakkam Rajappa¹ and Krishnamurthy Venkataraman², ¹Rheumatology and Immunology, GLB Hospitals, Chennai, India, ²Rheumatology, Apollo Speciality Hospitals, Chennai, India
Background/Purpose: Takayasu Arteritis (TA) in India frequently present with complications, indicating the need for a specific damage index to capture the accumulation of disease-related scars…
Abstract Number: 2196 • 2018 ACR/ARHP Annual Meeting
Kinetics of Tissue-Specific Distribution of 18f-Fluorodeoxyglucose in Positron Emission Tomography in Large Vessel Vasculitis
Joel S. Rosenblum¹, Kaitlin Quinn², Mark A. Ahlman³ and Peter C. Grayson⁴, ¹NIAMS, National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, ²Systemic Autoimmunity Branch, NIAMS, Bethesda, MD, ³Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, ⁴National Institute of Arthritis, Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, MD
Background/Purpose: 18F-fluorodeoxyglucose (FDG) PET may be used to quantify vascular inflammation in large-vessel vasculitis (LVV). Quantitative analysis of arterial FDG uptake has not been standardized. Delayed…
Abstract Number: 2746 • 2018 ACR/ARHP Annual Meeting
Tocilizumab Monotherapy for Large Vessel Vasculitis: Results of 104-Week Treatment of a Prospective, Single-Center, Open Study
Shuntaro Saito, Ayumi Okuyama, Yusuke Okada, Akiko Shibata, Ryota Sakai, Kentaro Chino, Takahiko Kurasawa, Tsuneo Kondo, Hirofumi Takei and Koichi Amano, Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
Background/Purpose: To evaluate the efficacy and safety of tocilizumab (TCZ) monotherapy for Large Vessel Vasculitis (LVV), including Takayasu arteritis (TAK) and Giant cell arteritis (GCA).…
Abstract Number: 2759 • 2018 ACR/ARHP Annual Meeting
Effect of Specific Treatments on Clinical, Serologic, and Imaging Assessments of Disease Activity in Large-Vessel Vasculitis
Shubhasree Banerjee¹, Kaitlin Quinn², Katherine B. Gribbons³, Joel S. Rosenblum⁴, Ali Civelek⁵, Elaine Novakovich⁶, Armin Bagheri¹, Peter A. Merkel⁷, Mark A. Ahlman⁸ and Peter C. Grayson⁹, ¹Systemic Autoimmunity Branch, NIAMS, NIH, Bethesda, MD, ²Systemic Autoimmunity Branch, NIAMS, Bethesda, MD, ³Systemic Autoimmunity Branch, National Institute of Arthritis and Skin and Musculoskeletal Disease, Bethesda, MD, ⁴NIAMS, National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, ⁵National Institutes of Health, Clinical Center, Radiology and Imaging Sciences, Bethesda, MD, ⁶National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁷University of Pennsylvania, Philadelphia, PA, ⁸Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, ⁹National Institute of Arthritis, Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, MD
Background/Purpose: Disease activity in large vessel vasculitis (LVV) is traditionally assessed by clinical and serologic (ESR, CRP) parameters. Imaging assessment, including 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET),…
Abstract Number: 2778 • 2018 ACR/ARHP Annual Meeting
High Prevalence of Vascular Surgery and Autoimmune Comorbidity in Takayasu Arteritis
Tsuyoshi Shirai¹, Tomoyuki Muto², Yuko Shirota¹, Hiroshi Fujii¹, Tomonori Ishii³ and Hideo Harigae¹, ¹Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, ²Tohoku University Graduate School of Medicine, Sendai, Japan, ³Clinical Research, Innovation and Education Center, Tohoku University Hospital, Sendai, Japan
Background/Purpose: Large vessel vasculitis (LVV) is the arteritis in aorta and its major branches, and classified into Takayasu arteritis (TAK) and giant cell arteritis (GCA).…
Abstract Number: 795 • 2017 ACR/ARHP Annual Meeting
Characteristics and Treatment Outcomes of Giant Cell Arteritis with Large-Vessel Lesions in a Nationwide, Retrospective Cohort Study in Japan
Takahiko Sugihara¹, Hitoshi Hasegawa², Haruhito Uchida³, Hajime Yoshifuji⁴, Yoshikazu Nakaoka⁵, Yoshiko Watanabe⁶, Eisuke Amiya⁷, Masanori Konishi⁸, Yasuhiro Katsumata⁹, Yoshinori Komagata¹⁰, Taio Naniwa^11,12, Takahiro Okazaki¹³, Yoshiya Tanaka¹⁴, Tsutomu Takeuchi¹⁵, Masayoshi Harigai¹⁶, Yoshihiro Arimura¹⁷ and Mitsuaki Isobe^8,18, ¹Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ²Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime, Japan, ³Department of Chronic Kidney Disease and Cardiovascular Disease, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ⁴Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁵Osaka University Graduate School of Medicine, Osaka, Japan, ⁶First Department of Physiology, Kawasaki Medical School, Kurashiki, Japan, ⁷Department of Cardiovascular Medicine, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ⁸Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan, ⁹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ¹⁰First Dept. of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan, ¹¹Division of Rheumatology, Dept of Internal Medicine,, Nagoya City University Hospital, Nagoya, Japan, ¹²Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, ¹³Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ¹⁴The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁵Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ¹⁶Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ¹⁷First Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan, ¹⁸Sakakibara Heart Institute, Tokyo, Japan
Background/Purpose: Giant cell arteritis (GCA) often affects aorta or its branches, but it is unclear whether the large-vessel (LV) lesions are associated with treatment outcomes.…
Abstract Number: 801 • 2017 ACR/ARHP Annual Meeting
PET-CT Findings and Clinical Outcomes in Takayasu Arteritis – Does 18F-Fluorodeoxyglucose Uptake in Arteries Predict Relapses?
Anna Larissa Faria Janes¹, Míriam Fang Castro¹, Bruna Savioli¹, Anne Elisabeth Diniz Arraes¹, Emilia Sato² and Alexandre W.S. Souza³, ¹Internal Medicine - Rheumatology Division, Universidade Federal de São Paulo - Escola Paulista de Medicina, São Paulo, Brazil, ²Rheumatology Division, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, ³Rheumatology Div/Dept of Med, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil
Background/Purpose: PET-CT scan with 18F-Fluorodeoxyglucose (18F-FDG) has been frequently used as a tool to assess disease activity in Takayasu arteritis (TA) and increased 18F-FDG uptake…
Abstract Number: 824 • 2017 ACR/ARHP Annual Meeting
Long Term Efficacy and Safety of Intravenous and Subcutaneous Biologics in Large Vessels Vasculitis: 21 Patients Belonging to a Single Italian Center from 2011 to 2017
Paola Toniati¹ and Angela Tincani², ¹RHEUMATOLOGY, SPEDALI CIVILI, BRESCIA, Italy, ²University and Spedali Civili of Brescia, Brescia, Italy
Background/Purpose: Large vessels vasculitis (LVV) is the most common form of primary vasculitis comprising giant cell arteritis (GCA) and Takayasu arteritis (TAK) and aortitis. Methods:…
Abstract Number: 1845 • 2017 ACR/ARHP Annual Meeting
Comparison of Magnetic Resonance Angiography (MRA) and 18f-Fluorodeoxyglucose Positron Emission Tomography (PET) in Large Vessel Vasculitis
Kaitlin A. Quinn^1,2, Ashkan Malayeri³, Mark Ahlman³, Armin Bagheri⁴, Robert Evers⁵, Ali Cahid Civelek³, Elaine Novakovich⁶ and Peter C. Grayson⁷, ¹Rheumatology, MedStar Georgetown University Hospital, Washington, DC, ²NIAMS/NIH, Bethesda, MD, ³Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, ⁴Vasculitis Translational Research Program, NIAMS, NIH, Bethesda, MD, ⁵NIH, Bethesda, MD, ⁶Systemic Autoimmunity Branch, NIAMS, National Institutes of Health, Bethesda, MD, ⁷National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD
Background/Purpose: Magnetic resonance imaging (MRI) and 18F-fluorodeoxyglucose positron emission tomography (PET) may provide unique or redundant information in large vessel vasculitis (LVV). The study objective…
Abstract Number: 2737 • 2017 ACR/ARHP Annual Meeting
Pulmonary Manifestations of Primary Systemic Vasculitides
Jean-Paul Makhzoum¹, Raashid Luqmani², Richard A. Watts³, Anthea Craven⁴, Peter A. Merkel⁵ and Christian Pagnoux⁶, ¹Rheumatology, Vasculitis Clinic, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ²Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ³Rheumatology Department, The Ipswich Hospital, Ipswich, Great Britain, ⁴Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, Oxford University Hospitals, Oxford, United Kingdom, ⁵Division of Rheumatology, University of Pennsylvania; Perelman School of Medicine, Philadelphia, PA, ⁶Rheumatology-Vasculitis clinic, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Pulmonary involvement in systemic primary vasculitides is diverse and occurs with variable incidence depending on the type of vasculitis. This study aimed to describe…
Abstract Number: 102 • 2017 ACR/ARHP Annual Meeting
Incorporating Temporal Artery Ultrasound in a UK District General Hospital with No Prior Colour Doppler Sonography Service: An Encouraging Preliminary Analysis
Othman Kirresh¹, Chintu Gademsetty² and Charles Li¹, ¹Rheumatology, NHS Royal Surrey County Hospital, Surrey, United Kingdom, ²Radiology, NHS Royal Surrey County Hospital, Surrey, United Kingdom
Background/Purpose: Temporal Arteritis (TA) is the most common large vessel vasculitis, affecting adults over the age of 50. It is associated with significant morbidity due…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].